insights_auto
Why is CYTK up 2.32%?
Dive Deeperchevron_right
CYTK:NASDAQ
Cytokinetics, Inc.
$66.16
arrow_upward
+2.32%(+1.50) 1D
$66.16
0.00% (0.00)
bedtimeAfter hours
Closed: Sep 28, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CYTK...
Open
$64.58
High
$66.41
Low
$64.25
Mkt. cap
9.20B
Avg. vol.
1.89M
Volume
0.00
52-wk high
$88.31
52-wk low
$50.15
EPS
-$7.22
Beta
0.36
Shares outstanding
139.02M
No. of employees
673
Open
$64.58
High
$66.41
Low
$64.25
Mkt. cap
9.20B
Avg. vol.
1.89M
Volume
0.00
52-wk high
$88.31
52-wk low
$50.15
EPS
-$7.22
Beta
0.36
Shares outstanding
139.02M
No. of employees
673
News stories
From web sources and news partners
Investing.com
·
2 hours ago
Cytokinetics CEO Robert Blum sells $490,949 in stock
Investing.com Canada
·
3 hours ago
Form 4 Cytokinetics Inc For: 29 September By Investing.com
AD HOC NEWS
·
14 hours ago
Cytokinetics stock gains 2.15 percent as analysts target USD 109.90
Simply Wall Street
·
3 days ago
Cytokinetics (CYTK) Pullback Puts Its Heart Drug Valuation Story Back In Focus
Profile
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function. Wikipedia
About Cytokinetics, Inc.
CEORobert I. Blum | Robert I. Blum
Employees673
Founded1997
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websitecytokinetics.com